- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on HLA-A2 Positive Cells Present
Total 884 results
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedMetastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm | HLA-A2 Positive Cells PresentUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRefractory Melanoma | HLA-A2 Positive Cells PresentUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | EBV-Positive Neoplastic Cells Present | HLA-A*0201 Positive Cells Present | Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Elevated WT1United States
-
Jonsson Comprehensive Cancer CenterCalifornia Institute for Regenerative Medicine (CIRM)TerminatedSarcoma | Unresectable Malignant Neoplasm | Locally Advanced Malignant Neoplasm | HLA-A*0201 Positive Cells Present | NY-ESO-1 PositiveUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Ovarian Carcinoma | HLA-A*0201 Positive Cells Present | COL6A3 Positive | PRAME PositiveUnited States
-
Jonsson Comprehensive Cancer CenterNovartis PharmaceuticalsWithdrawnRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells PresentUnited States
-
M.D. Anderson Cancer CenterCompletedRecurrent Synovial Sarcoma | HLA-A*0201 Positive Cells Present | NY-ESO-1 Positive Tumor Cells Present | Recurrent Myxoid LiposarcomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian CancerUnited States
-
Hadassah Medical OrganizationUnknownMetastatic Disease | High Risk HLA-A2+ Melanoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnMantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnAnaplastic Large Cell Lymphoma, ALK-Positive | CD30-Positive Neoplastic Cells Present | Systemic Anaplastic Large Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Donor | Hematopoietic Cell Transplant Recipient | HLA-A*0201 Positive Cells PresentUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); PfizerTerminatedChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts Under 15 Percent of Bone Marrow Nucleated Cells | Blasts Under 15 Percent of Peripheral Blood White Cells | Blasts Under 30 Percent of Bone Marrow Nucleated Cells | Blasts Under 30 Percent of Peripheral Blood White CellsUnited States
-
University Health Network, TorontoTakara Bio Inc.Active, not recruitingMelanoma | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Bladder Cancer | Liver Cancer | Synovial Sarcoma | NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsCanada
-
Roswell Park Cancer InstitutePfizerWithdrawnRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 Positive | Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Blasts 5 Percent or More of Peripheral Blood White Cells | Lymphoblasts... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Myelofibrosis | Chronic Lymphocytic Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome | Adult Acute Lymphoblastic Leukemia in Remission | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterAstraZenecaTerminatedOropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Non-Small Cell Lung Carcinoma | Recurrent Pleural Malignant Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage IV Pleural Malignant Mesothelioma AJCC v7 | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | HLA-A*0201 Positive... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Mesothelioma | CD30-Positive Neoplastic Cells PresentUnited States
-
William ShomaliIncyte CorporationRecruitingEosinophilia | Hypereosinophilic Syndrome | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | Splenomegaly | Hepatomegaly | Chronic Eosinophilic Leukemia, Not Otherwise Specified | JAK2 Gene Mutation | BCR-JAK2 Fusion Protein Expression | Blasts 20 Percent or Less of Peripheral Blood White... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedDiffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); ADC Therapeutics S.A.RecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells | CD22 PositiveUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | B Acute Lymphoblastic Leukemia With t(9;22)(q34... and other conditionsUnited States
-
City of Hope Medical CenterWithdrawnSezary Syndrome | Recurrent Mycosis Fungoides | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Mycosis Fungoides | Folliculotropic Mycosis Fungoides | CD30-Positive Neoplastic Cells Present | Refractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Double-Expressor Lymphoma | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAcute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditionsUnited States
-
University of Illinois at ChicagoWithdrawnKidney Transplant Rejection | Positive FCXM (T or B Cell Positive) | Positive CDC Cross-Match (B Cell Positive) | Kidney/Pancreas Transplant RejectionUnited States
-
Center for International Blood and Marrow Transplant...Patient-Centered Outcomes Research Institute; National Marrow Donor ProgramCompletedAdult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCTUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingVemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaBRAF V600E Mutation Present | Papillary CraniopharyngiomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated CellsUnited States
-
Fred Hutchinson Cancer CenterCompletedMyelodysplastic Syndrome (MDS) | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Blasts Under 5 Percent of Bone Marrow...United States
-
Lawrence D RechtSanofiRecruitingGlioblastoma | Malignant Glioma | Gliosarcoma | Glioblastoma With Primitive Neuronal Component | Oligodendroglial Component PresentUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
Charite University, Berlin, GermanyUniversity of LeipzigUnknownAcute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor AvailableGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Ziopharm OncologyCompletedAcute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated CellsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Mantle Cell Lymphoma | CCND1 Positive | CCND2 Positive | CCND3 Positive | CD20 Positive | Refractory Mantle Cell LymphomaUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); AmgenTerminatedStage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell CountUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Roswell Park Cancer InstituteCelgeneWithdrawnRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment LevelUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Blasts More Than 20 Percent of Bone Marrow Nucleated Cells | Blasts More Than 20 Percent of Peripheral Blood White CellsUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Southern CaliforniaNational Cancer Institute (NCI); Vasgene Therapeutics, Inc; Whittier FoundationTerminatedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia and other conditionsUnited States
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.Anhui Provincial HospitalNot yet recruitingCD19-positive Relapsed or Refractory B-cell MalignanciesChina
-
Jonathan Schoenfeld, MD, MPHNaverisRecruitingHPV Positive Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC... and other conditionsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompletedCD30-Positive Diffuse Large B-Cell Lymphoma | CD30 Positive Primary Mediastinal Large B-cell Lymphoma | CD30-Positive Gray Zone LymphomaUnited States
-
AC Camargo Cancer CenterRecruitingBreast Neoplasms | HER2-positive Breast Cancer | Circulating Tumor CellBrazil
-
Sumithira VasuKiadis PharmaRecruitingRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blasts 10 Percent or More of Bone Marrow Nucleated Cells | Allogeneic Stem Cell Transplant RecipientUnited States
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong